Jan Ohrstrom

Senior Executive with international experience in Biotechnology and Pharma. Management appointments in Large and Mid-Cap US/EU Biopharma companies. Proven track record with product approvals, financing, M&A and IPO. Part of the management Team that Roadshowed ZymoGenetics inc (Nasdaq: ZGEN) through Private Placement, IPO and follow-on offerings. Incorporated ProFibrix Inc in 2008, and as CEO in 2013 led ProFibrix through M&A with The Medicines Company after successful Phase 3 completion and product approvals in EU and US. Board appointments in private and public companies.

Present:
Independent Board Director of Polyganics BV
Chairman of the Board G-therapeutics
Chairman of the Board VarmX
Chairman of the Board Blaze Therapeutics Inc.

Previous:
Snr VP The Medicines Company
CEO Profibrix BV
Board Director Avigen Inc
Exec VP Mediquest Therapeutics Inc
Snr VP ZymoGenetics Inc
Director Novo Nordisk A/s